Targeting reactive oxygen species to overcome cisplatin resistance in lung cancer


  • Medhi Wangpaichitr Department of Veterans Affairs, Research Service, Miami, FL 33125 and Department of Surgery, Surgical Oncology, University of Miami, Miami. FL 33136
  • George Theodoropoulos Department of Veterans Affairs, Research Service, Miami, FL 33125
  • Niramol Savaraj Department of Veterans Affairs, Research Service, Miami, FL 33125 and Department of Medicine, Hematology/Oncology, University of Miami, Miami, FL 33136


lung cancer, cisplatin resistance, reactive oxygen species


Cisplatin resistance remains a major problem in the treatment of both small cell and non small cell lung cancer (NSCLC).  We have discovered that cisplatin resistant (CR) cells share one common biochemical parameter, increased reactive oxygen species (ROS), when compared to normal cells and  their parental cells counterparts.  Treating CR cells with either a ROS inducing agent (elesclomol), or an antioxidant agent (N-acetylcysteine) resulted in a significant growth inhibitory effect.  This suggested that ROS levels were an important component in the survival of these cells.  Co-treatment of cisplatin with NAC however resulted in and antagonistic effect, while elesclomol in combination with cisplatin treatment enhanced cisplatin sensitivity in CR cells.  Our findings suggest a novel approach to overcome CR in lung tumors. Combining a ROS inducing agent with cisplatin may prove to be clinically efficacious.



Arner, E. S., Nakamura, H., Sasada, T., Yodoi, J., Holmgren, A., & Spyrou, G. (2001). Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloro platinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med, 31(10), 1170-1178.

Berkenblit, A., Eder, J. P., Jr., Ryan, D. P., Seiden, M. V., Tatsuta, N., Sherman, M. L., et al. (2007). Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res, 13(2 Pt 1), 584-590.

Carney, D. N., Gazdar, A. F., Bepler, G., Guccion, J. G., Marangos, P. J., Moody, T. W., et al. (1985). Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res, 45(6), 2913-2923.

Clement, M. V., & Pervaiz, S. (1999). Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: an hypothesis. Free Radic Res, 30(4), 247-252.

Feun, L. G., Savaraj, N., Solomon, J., Liebmann, A., & Hurley, J. (1996). Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer. Am J Clin Oncol, 19(2), 190-192.

Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C. Y., Zhang, M., et al. (2008). Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther, 7(8), 2319-2327.

Kuo, M. T., Chen, H. H., Song, I. S., Savaraj, N., & Ishikawa, T. (2007). The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev, 26(1), 71-83.

Nagai, M., Vho, N., Cu, J., & Wada, Y. (2011). Elesclomol-Cu chelate selectively targets mitochondria to induce oxidative stress. Proceeding AACR 102nd Annual Meeting, Abstract No. 2093.

O'Day, S., Gonzalez, R., Lawson, D., Weber, R., Hutchins, L., Anderson, C., et al. (2009). Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol, 27(32), 5452-5458.

Pan, M. H., & Ho, C. T. (2008). Chemopreventive effects of natural dietary compounds on cancer development. Chem Soc Rev, 37(11), 2558-2574.

Pervaiz, S., & Clement, M. V. (2004). Tumor intracellular redox status and drug resistance--serendipity or a causal relationship? Curr Pharm Des, 10(16), 1969-1977.

Sasada, T., Nakamura, H., Ueda, S., Sato, N., Kitaoka, Y., Gon, Y., et al. (1999). Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med, 27(5-6), 504-514.

Savaraj, N., Wu, C. J., Xu, R., Lampidis, T., Lai, S., Donnelly, E., et al. (1997). Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol, 20(4), 398-403.

Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22(47), 7265-7279.

Song, I. S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., et al. (2004). Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther, 3(12), 1543-1549.

Toogood, P. L. (2008). Mitochondrial drugs. Curr Opin Chem Biol, 12(4), 457-463.

Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., et al. (2006). Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 10(3), 241-252.

Tuma, R. S. (2008). Reactive oxygen species may have antitumor activity in metastatic melanoma. J Natl Cancer Inst, 100(1), 11-12.

Vatanasapt, V., Sriamporn, S., & Vatanasapt, P. (2002). Cancer control in Thailand. Jpn J Clin Oncol, 32 Suppl, S82-91.

Wang, Y., Zeigler, M. M., Lam, G. K., Hunter, M. G., Eubank, T. D., Khramtsov, V. V., et al. (2007). The role of the NADPH oxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survival. Am J Respir Cell Mol Biol, 36(1), 68-77.

Wangpaichitr, M., Sullivan, E. J., Theodoropoulos, G., Wu, C., You, M., Feun, L. G., et al. (2012). The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther, 11(3), 604-615.

Wangpaichitr, M., Wu, C., You, M., Kuo, M. T., Feun, L., Lampidis, T., et al. (2008). Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol, 591(1-3), 124-127.

Wangpaichitr, M., Wu, C., You, M., Maher, J. C., Dinh, V., Feun, L. G., et al. (2009). N1,N3-Dimethyl-N1,N3-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers, 1(1), 23-28.

Witte, A. B., Anestal, K., Jerremalm, E., Ehrsson, H., & Arner, E. S. (2005). Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med, 39(5), 696-703.

Wu, C., Wangpaichitr, M., Feun, L., Kuo, M. T., Robles, C., Lampidis, T., et al. (2005). Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer, 4(1), 25.




How to Cite

Wangpaichitr, M. ., Theodoropoulos, G. ., & Savaraj, N. . (2023). Targeting reactive oxygen species to overcome cisplatin resistance in lung cancer. Journal of Current Science and Technology, 2(2), 143–150. Retrieved from



Research Article